Ingenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDA

Breakthrough Technology Empowers NK Cell Therapy for Acute Myeloid Leukemia DAEJEON, Korea, April 30, 2024 /PRNewswire/ — Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks